What insurance policy changes affect code Q89.2?

There are 2 tracked policy changes affecting code Q89.2, including updates from Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code Q89.2?

Payers that have issued tracked updates for code Q89.2 include: Aetna.

How do I get notified when code Q89.2 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code Q89.2. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code Q89.2?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

PAYER POLICY CHANGES

Q89.2 Insurance Policy Changes

ICD-10 Q89.2 is officially defined as "Congenital malformations of other endocrine glands." code Q89.2 is referenced in 2 tracked payer policy changes from Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code Q89.2 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Only a small number of policies match this filter. Check back as coverage expands.

Aetna · Identified Aug 14, 2026Medium impact
Allogeneic Processed Thymus Tissue–agdc (Rethymic) (CPB 1055, reviewed 2025-12-23)
Aetna considers a single administration of allogeneic processed thymus tissue-agdc (Rethymic) medically necessary for immune reconstitution in members 18 years of age or younger with congenital athymia when all criteria are met. Aetna considers all other indications experimental, investigational, or unproven. Members with severe combined immunodeficiency (SCID), preexisting cytomegalovirus or HIV infection, or any prior thymus tissue transplantation or Rethymic treatment are not eligible.
Aetna · Identified Aug 14, 2026Medium impact
Ethanol Injection for Thyroid Lesions and Other Selected Indications (CPB 0395, reviewed 2026-07-06)
Ethanol sclerotherapy of thyroglossal duct cysts is medically necessary only when a monocystic lesion is present, cystographic studies show no extravasation, and cytology shows the lesion is benign. Ethanol sclerotherapy is also medically necessary for symptomatic venous malformations of the head and neck, absolute ethanol injection is medically necessary for overt upper gastrointestinal bleeding, and ethanol ablation is medically necessary for benign thyroid nodules. Ethanol sclerotherapy for endometrioma, intradiscal radiopaque gelified ethanol injection for lumbar disc herniation, percutaneous ethanol injection for thyroid cancer, and ultrasound-guided ethanol sclerotherapy for Warthin's tumor are considered experimental, investigational, or unproven.

Watch Q89.2

Get one email when a payer policy names Q89.2, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Allogeneic Processed Thymus Tissue–agdc (Rethymic) (CPB 1055, reviewed 2025-12-23)

Ethanol Injection for Thyroid Lesions and Other Selected Indications (CPB 0395, reviewed 2026-07-06)

What insurance policy changes affect code Q89.2?

Which payers have updated policy for code Q89.2?

How do I get notified when code Q89.2 policy changes?

Why do payers change policies for code Q89.2?